load

Teraligen®
balanced medication for autonomic disorders

Teraligen® (alimemazine) 1-19 – reduces or completely eliminates manifestations of somatoform, as well as behavioral, and anxiety–depressive disorders, due to its influence on multiple receptors of the central and peripheral nervous systems (multimodal mechanism of action).

Teraligen has quickly gained popularity and secured solid positions both in adult and child therapy of various diseases and disorders, primarily in psychoneurology, surgery, anesthesiology and dermatology owing to a number of pharmacological properties of fundamental clinical importance and its multimodal mechanism of action. Alimemazine has a rich and diverse clinical research base, as well as global application experience..

The drug has proven effective in treating:

  • Teraligen is effective for somatoform disorders (somatic symptom disorder) treatment;
  • anxiety-depressive, behavioral disorders, stress manifestations, psychic tension, neurosis, anxiety, fear (phobias of various origins), hysteria, hypochondria, etc.;
  • sleep disorders, circadian dysregulation, disturbed sleep architectonics. Teraligen acts as a hypnotic (it has a sedative and hypnotic effect);
  • allergic reactions of different origin and localization (respiratory tract, skin). Teraligen has an antihistamine effect and antiallergic agent properties;
  • abdominal spasms and pain, discomfort in the gastrointestinal tract and other internal organs. Teraligen can be applied in complex therapy of functional illnesses;
  • decreases fluctuations in blood pressure, heart rhythm disturbances, pain, spasms in the chest. Teraligen contributes to the successful treatment of cardiovascular diseases as attendant agent;
  • cases of vomiting and coughing. Teraligen has an antitussive and antiemetic effect (affects the cough and vomiting center of the brain);
  • muscle spasms, tension and excess contractions, tremor (trembling) of limbs or trunk. Teraligen has antiparkinsonic, spasmolytic effect.

The drug is indicated for adults, the elderly and children from 7 years of age; available in two dosage forms: 5 mg tablets and intramuscular solution - 5 mg/ml.

Teraligen® can be easily and safely combined with various drugs and treatment methods due to its low risk of drug-drug interactions. High efficiency and favorable safety profile allow different specialists to widely use the drug in their therapeutic practice.


1Patient information leaflet for Teraligen® (alimemazine) Valenta (tablets).

2Patient information leaflet for Teraligen® (alimemazine) (intramuscular solution).

3PRODUCT MONOGRAPH PANECTYL (Trimeprazine Tartrate) 2.5 mg and 5 mg Tablets Antipruritic – Antihistaminic 8250 Décarie. 8250 Décarie Blvd, suite 110. Montréal, QC. Canada, H4P 2P5. Date of revision: December 11th 2015.

4Par Adolfo Fernandes-Zoila, Le Tartrate D’Alimemazine en pratique psychiatrique ambulatoire, Entretien therapeutique, 1961.

5Yakhno NN, Parfenov VA, Reikhart DV, Belostotsky AV, Arnautov VS. Multicentre non-interventional prospective observational program for studying the practice of Teraligen prescription to patients diagnosed with autonomic disorders (START-2: Russian experience with the validated Russian version of the 4DSQ questionnaire. Interim analysis). Journal of Neurology and Psychiatry 2015, 5.

6Etingof AM. Efficiency and safety of Teraligen administration in everyday practice. Pharmateka 2014, 19.

7Lyubimov AV, Karchaa AR. The adiministration of Teraligen in the therapy of suprasegmental (cerebral) autonomic disorders. Scientific bulletins of the Belgorod State University. Series: Medicine. Pharmatsia 2012, 4(17):20-5.

8Vorobyeva OV. Paradoxes of clinical manifestations and diagnostic criteria of anxiety disorders. Effecktivnaya pharmakoterapiya 2014, 31:14-20.

9Vorobyeva OV, Rusaya VV. Vegetative dysfunction associated with anxiety disorders. Effecktivnaya pharmakoterapiya 2011, 17:46-50.

10Akarachkova ES. On the issue of diagnosis and treatment of psychovegetative disorders in general somatic practice. Lechaschy vrach 2010, 10:5-8.

11Reshetova TV. The many faces of hysteria in general medical practice. Atmosphera. Nervnie bolezni 2008, 3:13-14.

12Pushkarev DF. Alimemazine in psychiatric practice and general medicine (literature review). Psikhicheskie rasstroystva v obschey medetsine 2013, 1:56-61.

13Bekker RA, Bykov YuV. Alimemazine: Application review. Psikiatria i psikhopharmakoterapiya, 18 (6).

14Masahiko Tatsumi, Karen Jansen, Randy D. Blakely, Elliott Richelson. Pharmacological profile of neuroleptics at human monoamine transporters European Journal of Pharmacology 368 (1999). 277–283.

15Petersen EN. Pre- and postsynaptic alpha-adrenoceptor antagonism by neuroleptics in vivo. Eur J Pharmacol 1981; 69 (4): 399–405.

16Wander TJ, Nelson A, Okazaki H et al. Antagonism by neuroleptics of serotonin 5-HT1A and 5-HT2 receptors of normal human brain in vitro. Eur J Pharmacol 1987; 143 (2): 279–82.

17Glusa E, Pertz HH. Further evidence that 5-HT-induced relaxation of pig pulmonary artery is mediated by endothelial 5-HT(2B) receptors. Br J Pharmacol 2000; 130 (3): 692–8.

18Hedlund PB. The 5-HT7 receptor and disorders of the nervous system: an overview. Psychopharmacology (Berl). 2009; 206 (3):345–54.

19Roth BL, Craigo SC, Choudhary MS et al. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 1994; 268 (3): 1403–10.